OssDsign announces strategic shift to become a pure play orthobiologics company
Uppsala, September 26, 2023, 17:31 CEST. OssDsign AB (publ) today announced a strategic shift to focus its operations on the orthobiologics business in the U.S, in order to increase shareholder value. The new strategy means that OssDsign will become a pure play orthobiologics company focusing on the nanosynthetic bone graft OssDsign Catalyst, an off-the-shelf product characterized by high scalability and high gross margins at 90 percent or above. All activities pertaining to the company’s patient-specific cranial implant business will be discontinued in a responsible manner by the end of